• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Septerna Inc.

    10/28/24 4:30:59 PM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEPN alert in real time by email
    8-K 1 d851611d8k.htm 8-K 8-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): October 28, 2024

     

     

    SEPTERNA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-42382   84-3891440

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    Septerna, Inc.

    250 East Grand Avenue

    South San Francisco, CA

      94080
    (Address of principal executive offices)   (Zip Code)

    Registrant’s telephone number, including area code: (650) 338-3533

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.001 par value per share   SEPN   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 5.03

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    Amendment and Restatement of Certification of Incorporation

    As previously disclosed in the Registration Statement on Form S-1, as amended (File No. 333-282469) (the “Registration Statement”), of Septerna, Inc. (the “Company”), and in connection with the completion of the initial public offering of the Company’s common stock (the “IPO”), on October 28, 2024, the Company filed its amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and the Company’s stockholders previously approved the Amended and Restated Certificate to be filed in connection with, and to be effective immediately prior to, the completion of the IPO. The Amended and Restated Certificate amends and restates the Company’s existing amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 500,000,000 shares of common stock; (ii) eliminate all references to the previously-existing series of preferred stock; and (iii) authorize 10,000,000 shares of undesignated preferred stock that may be issued from time to time by the Board in one or more series.

    The foregoing description of the Amended and Restated Certificate is qualified by reference to the full Amended and Restated Certificate, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

    Amendment and Restatement of Bylaws

    In addition, as previously disclosed in the Registration Statement, the amended and restated bylaws of the Company (the “Amended and Restated Bylaws”), previously approved by the Board and the Company’s stockholders, became effective as of the effectiveness of the Registration Statement on October 24, 2024. The Amended and Restated Bylaws amend and restate the Company’s bylaws in their entirety to, among other things: (i) eliminate the ability of the Company’s stockholders to take action by written consent in lieu of a meeting and call special meetings of stockholders; (ii) establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our Board; and (iii) conform to the amended provisions of the Amended and Restated Certificate.

    The foregoing description of the Amended and Restated Bylaws is qualified by reference to the full Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.2 and is incorporated herein by reference.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    3.1    Amended and Restated Certificate of Incorporation of Septerna, Inc.
    3.2    Amended and Restated Bylaws of Septerna, Inc.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          Septerna, Inc.
    Date: October 28, 2024     By:  

    /s/ Jeffrey Finer, M.D., Ph.D.

          Jeffrey Finer, M.D., Ph.D.
          President and Chief Executive Officer
    Get the next $SEPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEPN

    DatePrice TargetRatingAnalyst
    6/23/2025$26.00Buy
    H.C. Wainwright
    2/18/2025$14.00Overweight → Equal Weight
    Wells Fargo
    11/19/2024$38.00Overweight
    Analyst
    11/19/2024Buy
    TD Cowen
    11/19/2024$43.00Overweight
    Wells Fargo
    11/19/2024$50.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SEPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Septerna to Present at Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 3:45 p.m. ET in New York. A live webcast of the presentation will be available here and in the investors section of the company's website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of

      5/29/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

      Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, in Third Quarter of 2025 Ended First Quarter 2025 with $398.2 Million in Cash, Cash Equivalents and Marketable Securities; Novo Nordisk Collaboration to Significantly Extend Prior Runway Guidance of Early 2028 SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pi

      5/15/25 4:01:00 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

      Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 financial results. "Our Native Comp

      3/27/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    SEC Filings

    See more
    • SEC Form 8-K filed by Septerna Inc.

      8-K - Septerna, Inc. (0001984086) (Filer)

      6/18/25 4:31:30 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.

      SCHEDULE 13G/A - Septerna, Inc. (0001984086) (Subject)

      6/10/25 10:55:12 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Septerna Inc.

      SCHEDULE 13G/A - Septerna, Inc. (0001984086) (Subject)

      5/15/25 4:37:36 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care